A comparison between enprostil and ranitidine in the management of gastric ulceration.

Abstract

In a randomly allocated, double-blind, endoscopically controlled study, 98 patients with gastric ulcers were treated with either (a synthetic prostaglandin of E2-like structure) enprostil 70 micrograms b.d. or 150 mg ranitidine b.d. The healing rates at 4, 8 and 12 weeks were enprostil 57, 91 and 94% and for ranitidine 55, 88 and 98%, respectively. Following ulcer healing, half the patients were followed for 1 year without treatment and the others were given 70 micrograms enprostil nocte. Endoscopy was repeated in both groups after 6 and 12 months or if dyspeptic symptoms returned. The recurrence rate without maintenance at 6 and 12 months, following ranitidine therapy, was 67 and 75%, and after enprostil therapy 50 and 61%, respectively. On maintenance enprostil, the recurrence rates were 28 and 40%. Forty-seven per cent of patients who completed maintenance treatment had a proven ulcer recurrence within 6 months of stopping therapy. Diarrhoea was a common side-effect of enprostil therapy. Seven patients were withdrawn because of diarrhoea or abdominal pain.

• Authors: A G Morgan, C Pacsoo, P Taylor, W A McAdam
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 4 Issue 6 Pg. 635-41 (Dec 1990) ISSN: 0269-2813 [Print] England
• PMID: 2129650 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ranitidine
• Enprostil

Topics

• Double-Blind Method
• Endoscopy, Gastrointestinal
• Enprostil (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Ranitidine (adverse effects, therapeutic use)
• Recurrence
• Stomach Ulcer (drug therapy, pathology)